Aleksander Prejbisz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/997952/publications.pdf

Version: 2024-02-01

129 papers 5,047 citations

32 h-index 102487 66 g-index

134 all docs

134 docs citations

times ranked

134

5283 citing authors

#	Article	IF	CITATIONS
1	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes and Endocrinology,the, 2017, 5, 689-699.	11.4	595
2	Effects of Renal Sympathetic Denervation on Blood Pressure, Sleep Apnea Course, and Glycemic Control in Patients With Resistant Hypertension and Sleep Apnea. Hypertension, 2011, 58, 559-565.	2.7	427
3	Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovascular Research, 2020, 116, 1688-1699.	3.8	282
4	Cardiovascular manifestations of phaeochromocytoma. Journal of Hypertension, 2011, 29, 2049-2060.	0.5	224
5	Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial. Lancet Diabetes and Endocrinology, the, 2016, 4, 739-746.	11.4	208
6	Activation of Human T Cells in Hypertension. Hypertension, 2016, 68, 123-132.	2.7	191
7	Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. Journal of Hypertension, 2020, 38, 1443-1456.	0.5	190
8	Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension â^—. Journal of Hypertension, 2020, 38, 1919-1928.	0.5	151
9	Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. Clinical Chemistry, 2018, 64, 1646-1656.	3.2	121
10	Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1122-1132.	3.6	120
11	Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatographytandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma. Annals of Clinical Biochemistry, 2013, 50, 147-155.	1.6	99
12	Quality of Life in Primary Aldosteronism: A Comparative Effectiveness Study of Adrenalectomy and Medical Treatment. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 16-24.	3.6	99
13	Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma. Annals of Clinical Biochemistry, 2013, 50, 62-69.	1.6	98
14	Biochemical diagnosis of phaeochromocytoma using plasmaâ€free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. Clinical Endocrinology, 2014, 80, 478-486.	2.4	96
15	Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 111-115.	2.8	95
16	Simultaneous liquid chromatography tandem mass spectrometric determination of urinary free metanephrines and catecholamines, with comparisons of free and deconjugated metabolites. Clinica Chimica Acta, 2013, 418, 50-58.	1.1	82
17	Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma. European Journal of Endocrinology, 2017, 177, 103-113.	3.7	82
18	Decreased plasma concentration of a novel anti-inflammatory proteinâ€"adiponectinâ€"in hypertensive men with coronary artery disease. Thrombosis Research, 2003, 110, 365-369.	1.7	80

#	Article	IF	CITATIONS
19	PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Archives of Medical Science, 2021, 17, 1447-1547.	0.9	78
20	Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea. Hypertension, 2018, 72, 381-390.	2.7	73
21	Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. European Journal of Endocrinology, 2019, 181, 409-420.	3.7	58
22	Use of Steroid Profiling Combined With Machine Learning for Identification and Subtype Classification in Primary Aldosteronism. JAMA Network Open, 2020, 3, e2016209.	5.9	53
23	Carotid Intima-Media Thickness as a Marker of Cardiovascular Risk in Hypertensive Patients With Coronary Artery Disease. American Journal of Hypertension, 2007, 20, 1058-1064.	2.0	50
24	Reference intervals for LC-MS/MS measurements of plasma free, urinary free and urinary acid-hydrolyzed deconjugated normetanephrine, metanephrine and methoxytyramine. Clinica Chimica Acta, 2019, 490, 46-54.	1.1	50
25	Relationship between renal resistive index and early target organ damage in patients with never treated essential hypertension. Blood Pressure, 2009, 18, 55-61.	1.5	48
26	Measurements of plasma metanephrines by immunoassay vs liquid chromatography with tandem mass spectrometry for diagnosis of pheochromocytoma. European Journal of Endocrinology, 2015, 172, 251-260.	3.7	47
27	Przypadkowo wykryty guz nadnercza (incydentaloma) u dorosÅ,ych — zasady postÄ™powania rekomendowane przez Polskie Towarzystwo Endokrynologiczne. Endokrynologia Polska, 2016, 67, 234-258.	1.0	46
28	Lifestyle, psychological, socioeconomic and environmental factors and their impact on hypertension during the coronavirus disease 2019 pandemic. Journal of Hypertension, 2021, 39, 1077-1089.	0.5	44
29	Cardiovascular risk factors in hypertensive patients with coronary artery disease and coexisting renal artery stenosis. Journal of Hypertension, 2007, 25, 663-670.	0.5	39
30	Testing new susceptibility genes in the cohort of apparently sporadic phaeochromocytoma/paraganglioma patients with clinical characteristics of hereditary syndromes. Clinical Endocrinology, 2013, 79, 817-823.	2.4	38
31	Characterization of insomnia in patients with essential hypertension. Blood Pressure, 2006, 15, 213-219.	1.5	37
32	Primary Aldosteronism and Obstructive Sleep Apnea: Is This A Bidirectional Relationship?. Hormone and Metabolic Research, 2017, 49, 969-976.	1.5	34
33	Genetic investigation of fibromuscular dysplasia identifies risk loci and shared genetics with common cardiovascular diseases. Nature Communications, 2021, 12, 6031.	12.8	34
34	The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI)â€"clinical phenotypes and their predictors based on a cohort of 1000 patients. Cardiovascular Research, 2021, 117, 950-959.	3.8	33
35	Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma. Clinical Chemistry and Laboratory Medicine, 2021, 59, 353-363.	2.3	32
36	Obstructive Sleep Apnea–Induced Neurogenic Nocturnal Hypertension. Hypertension, 2021, 77, 1047-1060.	2.7	31

#	Article	IF	CITATIONS
37	Independent association of obstructive sleep apnea with left ventricular geometry and systolic function in resistant hypertension: the RESIST-POL study. Sleep Medicine, 2014, 15, 1302-1308.	1.6	30
38	A registry-based study of thyroid paraganglioma: histological and genetic characteristics. Endocrine-Related Cancer, 2015, 22, 191-204.	3.1	29
39	Impact of Screening Kindreds for SDHD p.Cys11X as a Common Mutation Associated with Paraganglioma Syndrome Type 1. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4818-4825.	3.6	28
40	Dopamine and Dopa Urinary Excretion in Patients with Pheochromocytoma–Diagnostic Implications. Blood Pressure, 2001, 10, 212-216.	1.5	26
41	Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine. Annals of Clinical Biochemistry, 2014, 51, 38-46.	1.6	26
42	Adrenal Vein Sampling Is the Preferred Method to Select Patients With Primary Aldosteronism for Adrenalectomy. Hypertension, 2018, 71, 10-14.	2.7	26
43	Relationship between primary aldosteronism and obstructive sleep apnoea, metabolic abnormalities and cardiac structure in patients with resistant hypertension. Endokrynologia Polska, 2013, 64, 363-367.	1.0	24
44	2015 guidelines for the management of hypertension. Recommendations of the Polish Society of Hypertension $\hat{a} \in \mathbb{Z}^n$ short version. Kardiologia Polska, 2015, 73, 676-700.	0.6	24
45	Growth Rate of Paragangliomas Related to Germline Mutations of the SDHx Genes. Endocrine Practice, 2017, 23, 342-352.	2.1	23
46	High incidence and clinical characteristics of fibromuscular dysplasia in patients with spontaneous cervical artery dissection: The ARCADIA-POL study. Vascular Medicine, 2019, 24, 112-119.	1.5	23
47	Relationship between obstructive sleep apnea and markers of cardiovascular alterations in never-treated hypertensive patients. Hypertension Research, 2014, 37, 573-579.	2.7	20
48	Systematic and Multidisciplinary Evaluation of Fibromuscular Dysplasia Patients Reveals High Prevalence of Previously Undetected Fibromuscular Dysplasia Lesions and Affects Clinical Decisions. Hypertension, 2020, 75, 1102-1109.	2.7	20
49	Rare loss-of-function mutations of <i>PTGIR</i> are enriched in fibromuscular dysplasia. Cardiovascular Research, 2021, 117, 1154-1165.	3.8	20
50	Management of hypertension in pregnancy: prevention, diagnosis, treatment and long‑term prognosis. Kardiologia Polska, 2019, 77, 757-806.	0.6	20
51	Next-generation panel sequencing identifies NF1 germline mutations in three patients with pheochromocytoma but no clinical diagnosis of neurofibromatosis type 1. European Journal of Endocrinology, 2018, 178, K1-K9.	3.7	19
52	Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1111-e1128.	3.6	19
53	Metabolic impact of pheochromocytoma/paraganglioma: targeted metabolomics in patients before and after tumor removal. European Journal of Endocrinology, 2019, 181, 647-657.	3.7	19
54	Blood Pressure and Arterial Stiffness in Association With Aircraft Noise Exposure:Long-Term Observation and Potential Effect of COVID-19 Lockdown. Hypertension, 2022, 79, 325-334.	2.7	19

#	Article	IF	CITATIONS
55	Plasma Steroid Profiling in Patients With Adrenal Incidentaloma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1181-e1192.	3.6	19
56	Renal Artery Stenosis in Patients With Resistant Hypertension. American Journal of Cardiology, 2013, 112, 1417-1420.	1.6	18
57	Determinants of concentric left ventricular hypertrophy in patients with resistant hypertension: RESIST-POL study. Hypertension Research, 2015, 38, 545-550.	2.7	18
58	Echocardiographic assessment of left ventricular morphology and function in patients with fibromuscular dysplasia. Journal of Hypertension, 2018, 36, 1318-1325.	0.5	18
59	Left Ventricular Structural and Functional Alterations in Patients With Pheochromocytoma/Paraganglioma Before and After Surgery. JACC: Cardiovascular Imaging, 2020, 13, 2498-2509.	5.3	18
60	Assessment of adherence to treatment in patients with resistant hypertension using toxicological serum analysis. A subgroup evaluation of the RESIST-POL study. Polish Archives of Internal Medicine, 2015, 125, 65-72.	0.4	18
61	Lack of utility of SDHB mutation testing in adrenergic metastatic phaeochromocytoma. European Journal of Endocrinology, 2015, 172, 89-95.	3.7	17
62	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3374-e3383.	3.6	17
63	Primary aldosteronism is highly prevalent in patients with hypertension and moderate to severe obstructive sleep apnea. Journal of Clinical Sleep Medicine, 2021, 17, 629-637.	2.6	17
64	On the nature of heart rate variability in a breathing normal subject: A stochastic process analysis. Chaos, 2009, 19, 028504.	2.5	15
65	Prognostic value of renal fractional flow reserve in blood pressure response after renal artery stenting (PREFER study). Cardiology Journal, 2013, 20, 418-422.	1.2	15
66	Current progress in clinical, molecular, and genetic aspects of adult fibromuscular dysplasia. Cardiovascular Research, 2022, 118, 65-83.	3.8	14
67	Usefulness of Somatostatin Receptor Scintigraphy (^{99m} Tc-[HYNIC,) Tj ETQq1 1 0.784314 with <i>SDHx</i> Gene-Related Pheochromocytomas and Paragangliomas Detected by Computed Tomography, Neuroendocrinology, 2015, 101, 321-330.	rgBT /Ove 2.5	erlock 10 Tf 13
68	Relationship between hemodynamic parameters of renal artery stenosis and the changes of kidney function after renal artery stenting in patients with hypertension and preserved renal function. Blood Pressure, 2015, 24, 30-34.	1.5	13
69	Renal resistive index in patients with true resistant hypertension: results from the RESIST-POL study. Kardiologia Polska, 2016, 74, 142-150.	0.6	13
70	Mediastinal paragangliomas related to SDHx gene mutations. Kardiochirurgia I Torakochirurgia Polska, 2016, 3, 276-282.	0.1	12
71	Subclinical Mood and Cognition Impairments and Blood Pressure Control in a Large Cohort of Elderly Hypertensives. Journal of the American Medical Directors Association, 2016, 17, 864.e17-864.e22.	2.5	12
72	Adrenomedullary function, obesity and permissive influences of catecholamines on body mass in patients with chromaffin cell tumours. International Journal of Obesity, 2019, 43, 263-275.	3.4	12

#	Article	IF	Citations
73	Beyond Atherosclerosis and Fibromuscular Dysplasia: Rare Causes of Renovascular Hypertension. Hypertension, 2021, 78, 898-911.	2.7	12
74	Factors associated with resistant hypertension in a large cohort of hypertensive patients: the Pol-Fokus study. Polish Archives of Internal Medicine, 2015, 125, 249-259.	0.4	12
75	Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine. Endocrine-Related Cancer, 2022, 29, 213-224.	3.1	12
76	Cardiac arrests, atrioventricular block, and pheochromocytoma. American Journal of Hypertension, 2004, 17, 544-545.	2.0	11
77	Assessment of renal artery stenosis using both resting pressures ratio and fractional flow reserve – Relationship to angiography and ultrasonography. Blood Pressure, 2011, 20, 211-217.	1.5	11
78	Factors Associated With Diastolic Dysfunction in Patients With Resistant Hypertension: Resist-POL Study. American Journal of Hypertension, 2015, 28, 307-311.	2.0	11
79	Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging. Endocrine Connections, 2018, 7, 1168-1177.	1.9	11
80	The coexistence of acute aortic dissection with autosomal dominant polycystic kidney disease - description of two hypertensive patients. Blood Pressure, 2004, 13, 283-286.	1.5	10
81	Effect of percutaneous renal denervation on blood pressure level and sympathetic activity in a patient with polycystic kidney disease. Clinical Research in Cardiology, 2014, 103, 251-253.	3.3	10
82	Pregnancy-Related Complications in Patients With Fibromuscular Dysplasia. Hypertension, 2020, 76, 545-553.	2.7	10
83	Malignant hypertension: new aspects of an old clinical entity. Polish Archives of Internal Medicine, 2015, 126, 86-93.	0.4	10
84	Pulmonary artery dilation indicates severe obstructive sleep apnea in patients with resistant hypertension: the Resist-POL Study. Polish Archives of Internal Medicine, 2016, 126, 222-229.	0.4	10
85	Genetic Study of <i>PHACTR1</i> and Fibromuscular Dysplasia, Meta-Analysis and Effects on Clinical Features of Patients. Hypertension, 2020, 76, e4-e7.	2.7	9
86	Pheochromocytoma Presenting as Takotsubo-Like Cardiomyopathy Following Delivery. Endocrine Practice, 2014, 20, 233-236.	2.1	8
87	Hypertension in patients with Alzheimer's diseaseâ€"prevalence, characteristics, and impact on clinical outcome. Experience of one neurology center in Poland. Journal of the American Society of Hypertension, 2015, 9, 711-724.	2.3	8
88	Altered plasma fibrin clot properties in hypertensive patients with obstructive sleep apnoea are improved by continuous positive airway pressure treatment. Journal of Hypertension, 2017, 35, 1035-1043.	0.5	8
89	Improved Diagnostic Accuracy of Clonidine Suppression Testing Using an Age-Related Cutoff for Plasma Normetanephrine. Hypertension, 2022, 79, 1257-1264.	2.7	8
90	The 24-h blood pressure measurement may predict mortality and cardiovascular events in hypertensive patients with coronary artery disease. Blood Pressure Monitoring, 2009, 14, 99-102.	0.8	7

#	Article	IF	CITATIONS
91	Dissecting visceral fibromuscular dysplasia reveals a new vascular phenotype of the disease: a report from the ARCADIA-POL study. Journal of Hypertension, 2020, 38, 737-744.	0.5	7
92	Effects of renal sympathetic denervation on blood pressure and glycaemic control in patients with true resistant hypertension: results of Polish Renal Denervation Registry (RDN-POL Registry). Kardiologia Polska, 2016, 74, 961-968.	0.6	7
93	Editorial Renal denervation after the symplicity HTN-3 trial. Postepy W Kardiologii Interwencyjnej, 2014, 2, 75-77.	0.2	6
94	Evaluation of Head and Neck Paragangliomas by Computed Tomography in Patients with Pheochromocytoma-Paraganglioma Syndromes. Polski Przeglad Radiologii I Medycyny Nuklearnej, 2016, 81, 510-518.	1.0	6
95	Relationship between gender and clinical characteristics, associated factors, and hypertension treatment in patients with resistant hypertension. Kardiologia Polska, 2017, 75, 421-431.	0.6	6
96	Adrenomedullin concentrations at two time points following myocardial infarction and prediction of mid-term outcomes. Archives of Medical Science, 2011, 6, 971-976.	0.9	5
97	Smaller caliber renal arteries are a novel feature of uromodulin-associated kidney disease. Kidney International, 2015, 88, 160-166.	5.2	5
98	Renal denervation – can we press the "ON―button again?. Postepy W Kardiologii Interwencyjnej, 2018, 14, 321-327.	0.2	5
99	Prevalence of smoking and clinical characteristics in fibromuscular dysplasia. The ARCADIA-POL study. Blood Pressure, 2019, 28, 49-56.	1.5	5
100	Metastatic pheochromocytoma and paraganglioma: signs and symptoms related to catecholamine secretion. Discover Oncology, 2021, 12, 9.	2.1	5
101	Optimized procedures for testing plasma metanephrines in patients on hemodialysis. Scientific Reports, 2021, 11, 14706.	3.3	5
102	A single-centre experience of the implementation of adrenal vein sampling procedure: the impact on the diagnostic work-up in primary aldosteronism. Kardiologia Polska, 2017, 75, 28-34.	0.6	5
103	Expert reviews Renal denervation – current evidence and perspectives. Postepy W Kardiologii Interwencyjnej, 2013, 4, 362-368.	0.2	4
104	Preanalytical Considerations and Outpatient Versus Inpatient Tests of Plasma Metanephrines to Diagnose Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3689-e3698.	3.6	4
105	Reduced Kidney Function Estimated by Cystatin C and Clinical Outcomes in Hypertensive Patients with Coronary Artery Disease: Association with Homocysteine and Other Cardiovascular Risk Factors. Kidney and Blood Pressure Research, 2010, 33, 139-148.	2.0	3
106	Retinal arterial remodeling in patients with pheochromocytoma or paraganglioma and its reversibility following surgical treatment. Journal of Hypertension, 2020, 38, 1551-1558.	0.5	3
107	Longitudinal changes in maternal left atrial volume index and uterine artery pulsatility indices in uncomplicated pregnancy. American Journal of Obstetrics and Gynecology, 2021, 224, 221.e1-221.e15.	1.3	3
108	Reninâ€'secreting juxtaglomerular cell tumor of the kidney causing severe hypertension and polyuria. Polish Archives of Internal Medicine, 2014, 124, 207-208.	0.4	3

#	Article	IF	CITATIONS
109	2019 Guidelines for the Management of Hypertension â€" Part 8â€"9. Arterial Hypertension, 2019, 23, 203-239.	0.3	3
110	Transient dynamic left ventricular outflow tract obstruction in a patient with pheochromocytoma. Kardiologia Polska, 2014, 72, 472-472.	0.6	3
111	Intra-renal blood flow parameters assessed by doppler sonography in hypertensive patients with fibromuscular dysplasia – relationship to renal function and target organ damage. The ARCADIA-POL study. Polish Archives of Internal Medicine, 2019, 129, 234-241.	0.4	3
112	Primary aldosteronism â€" recent progress and current concepts. Endokrynologia Polska, 2013, 64, 312-318.	1.0	2
113	Stosowanie skojarzenia beta-adrenolityku i inhibitora konwertazy angiotensyny w terapii nadciÅ≀nienia tętniczego — spojrzenie hipertensjologa. Kardiologia Polska, 2017, 75, 13-18.	0.6	2
114	Single-pill combinations (SPCs) and treatment of arterial hypertension in Poland. Expert consensus statement of the Polish Society of Hypertension and Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. Kardiologia Polska, 2017, 75, 1357-1367.	0.6	2
115	Phaeochromocytoma in a 86-year-old patient presenting with reversible myocardial dysfunction. Blood Pressure, 2011, 20, 383-386.	1.5	1
116	Reduced left ventricular strain is related to blood parameters in patients with polycythemia vera. International Journal of Cardiology, 2017, 226, 34-37.	1.7	1
117	Response to Renal Denervation for Sleep Apnea and Resistant Hypertension: Alternative or Complementary to Effective Continuous Positive Airway Pressure Treatment?. Hypertension, 2011, 58, .	2.7	0
118	CD3 ALDOSTERONISM, HEART AND VESSELS. Artery Research, 2015, 12, 1.	0.6	0
119	Secondary Hyperaldosteronism. , 2019, , 664-667.		0
120	Intrarenal hemodynamics and kidney function in pheochromocytoma and paraganglioma before and after surgical treatment. Blood Pressure, 2021, 30, 1-8.	1.5	0
121	Detection of pheochromocytoma by enzyme immunoassay measurements of plasma metanephrines requires appropriately established upper cut-offs of reference intervals. Endocrine Abstracts, 0, , .	0.0	O
122	The issue of treatment-resistant hypertension in clinical practice. Pediatria I Medycyna Rodzinna, 2014, 1, 57-68.	0.1	0
123	The issue of treatment-resistant hypertension in clinical practice. Pediatria I Medycyna Rodzinna, 2014, 10, 152-162.	0.1	O
124	Trends for beta-blockers use in a large cohort of Polish hypertensive patients — Pol-Fokus Study. Arterial Hypertension, 2015, 19, 120-128.	0.3	0
125	Leki zÅ,oÅ ¹ ⁄4one w terapii nadciÅ≀nienia tÄ™tniczego w Polsce. Stanowisko Ekspertów Polskiego Towarzystwa NadciÅ≀nienia TÄ™tniczego oraz Sekcji Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Arterial Hypertension, 2017, 21, 105-115.	0.3	O
126	Pheochromocytoma and Paraganglioma. Updates in Hypertension and Cardiovascular Protection, 2020, , 109-125.	0.1	0

#	Article	IF	CITATIONS
127	2021 PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on the diagnosis and therapy of lipid disorders in Poland. Diagnostyka Laboratoryjna I WiadomoÅ·ci PTDL, 2021, 57, 1-99.	0.1	0
128	Fibrin clot properties and fibrinolysis in patients with endocrine hypertension due to aldosterone or catecholamines excess. Clinical Endocrinology, $2021, \ldots$	2.4	0
129	Malignant hypertension: new aspects of an old clinical entity. Polish Archives of Internal Medicine, 2015, 126, 86-93.	0.4	0